CAS No.: 2361290-85-7
Molecular Weight: 148.42 kDa | Isotype: Human IgG1 kappa
Dosage Form: Injection | Manufacturer: Guangdong Hengrui Pharmaceutical
Product Overview
Recaticimab (Synonyms: SHR-1209), trade name Aixin'an®, is a fully human monoclonal anti-PCSK9 antibody, a China-developed innovative drug, mainly used for lipid-lowering therapy with significant efficacy and good safety.
Mechanism of Action
• Specifically binds to PCSK9, blocking its interaction with LDL receptors, preventing PCSK9-mediated degradation of LDLR, and increasing LDL-C clearance to reduce blood lipid levels.
• Increases the number of LDL receptors on hepatocyte surfaces, effectively lowering LDL-C, TC and ApoB levels, and reducing the risk of atherosclerotic cardiovascular disease (ASCVD).
Indications
Approved (NMPA, China): Combined with statins (or other lipid-lowering therapies) for adult patients with primary hypercholesterolemia (including HeFH) and mixed dyslipidemia who fail to reach LDL-C targets with moderate/high-dose statins; or monotherapy for non-familial hypercholesterolemia and mixed dyslipidemia patients.
Molecular Weight: 143.02 kDa | Isotype: Human IgG4 kappa
Dosage Form: Injection (150mg/1ml) | Manufacturer: Shanghai Junshi Biosciences
China [CN] 
Click enlarge Image